REVB: Revelation Biosciences Inc. Stocks News on May 22, 2025

REVB

Zacks Small Cap Research

13 days ago

REVB On Track and Exploring New Markets

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

REVB

Business Wire

14 days ago

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients

REVB

Business Wire

23 days ago

Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients

REVB

Zacks Small Cap Research

23 days ago

REVB Announces Major Treatment Expansion

REVB

Insider Monkey

a month ago

Why Revelation Biosciences Inc. (REVB) Went Down On Thursday?

REVB

MT Newswires

2 months ago

Top Premarket Decliners

REVB

Zacks Small Cap Research

2 months ago

REVB Announces Positive Test Results

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

REVB

Business Wire

2 months ago

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

REVB

Business Wire

2 months ago

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

REVB

Zacks Small Cap Research

3 months ago

REVB Starts 2025 With Bright Future Ahead

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

REVB

Business Wire

3 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

REVB

Business Wire

3 months ago

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

REVB

Business Wire

3 months ago

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

REVB

Zacks Small Cap Research

4 months ago

REVB Start 1B Trial and Announces Split

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

REVB

Business Wire

4 months ago

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

REVB

Business Wire

4 months ago

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

REVB

Business Wire

4 months ago

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

Nasdaq Grants Revelation Biosciences Inc. Continued Listing

REVB

Business Wire

5 months ago

Nasdaq Grants Revelation Biosciences Inc. Continued Listing

REVB

MT Newswires

6 months ago

Sector Update: Health Care Stocks Mixed Late Afternoon

REVB

MT Newswires

6 months ago

Top Midday Decliners

REVB

Business Wire

6 months ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

REVB

Zacks Small Cap Research

6 months ago

REVB Gets FDA Go Ahead

REVB

Business Wire

6 months ago

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

REVB

Business Wire

6 months ago

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

REVB

Zacks Small Cap Research

6 months ago

REVB Results Set Stage for Future Growth

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

REVB

Business Wire

6 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10

REVB

Business Wire

8 months ago

Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10

REVB

MT Newswires

9 months ago

Top Premarket Decliners

REVB

Business Wire

9 months ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds

REVB

Zacks Small Cap Research

9 months ago

REVB: Bolsters Cash Amid Positive Trial Results

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

REVB

Business Wire

9 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

REVB

Zacks Small Cap Research

10 months ago

REVB Releases Positive Test Results—Potential Catalyst

Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?

REVB

Benzinga

a year ago

Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?

REVB

MT Newswires

a year ago

Revelation Biosciences Shares Jump on Positive Results for Investigational Drug Gemini

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

REVB

Business Wire

a year ago

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini

REVB

Business Wire

a year ago

Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini

REVB

Zacks Small Cap Research

a year ago

REVB: In Great Position For Testing

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024

REVB

Business Wire

a year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024

REVB

Zacks Small Cap Research

a year ago

REVB Begins Trials with Good Cash on Hand

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023

REVB

Business Wire

a year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023

Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)

REVB

Business Wire

a year ago

Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)

Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference

REVB

Business Wire

a year ago

Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

REVB

Business Wire

a year ago

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

REVB

Business Wire

a year ago

Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering

REVB

Business Wire

a year ago

Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering

Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering

REVB

Business Wire

a year ago

Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering

REVB

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 01/31/2024

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

REVB

Business Wire

a year ago

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

REVB

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 01/30/2024

REVB

Zacks Small Cap Research

a year ago

REVB Continues March to Trials

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

REVB

GlobeNewswire

a year ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

SOBRsafe Gaining Momentum in Behavioral Health, Signs Fourth Customer

REVB

ACCESSWIRE

a year ago

SOBRsafe Gaining Momentum in Behavioral Health, Signs Fourth Customer

LENSAR Decline Means Insider Profits Down To US$42k

REVB

Simply Wall St.

a year ago

LENSAR Decline Means Insider Profits Down To US$42k

Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024

REVB

Business Wire

a year ago

Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024

CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics

REVB

GlobeNewswire

a year ago

CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics

Datasea Enters into Agreement with U.S. Marketing Firm to Promote and Market its Innovative Intelligent Acoustics Products

REVB

PR Newswire

a year ago

Datasea Enters into Agreement with U.S. Marketing Firm to Promote and Market its Innovative Intelligent Acoustics Products

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

REVB

GlobeNewswire

a year ago

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

LED Lighting, EV Charging and Electrical Maintenance Provider Orion Announces Preliminary Q3’24 Revenue Growing to $25.8M-$26.2M and Improved Cash Position; Updates FY 2024 Anticipated Revenue Outlook to $90M-$95M

REVB

GlobeNewswire

a year ago

LED Lighting, EV Charging and Electrical Maintenance Provider Orion Announces Preliminary Q3’24 Revenue Growing to $25.8M-$26.2M and Improved Cash Position; Updates FY 2024 Anticipated Revenue Outlook to $90M-$95M

Phoenix Issues Preliminary Guidance Following the Purchase of Proterra's Transit Business

REVB

ACCESSWIRE

a year ago

Phoenix Issues Preliminary Guidance Following the Purchase of Proterra's Transit Business

SOBRsafe Selected as Exclusive Alcohol Data Partner for Next-Generation Digital Healthcare Platform

REVB

ACCESSWIRE

a year ago

SOBRsafe Selected as Exclusive Alcohol Data Partner for Next-Generation Digital Healthcare Platform

XORTX Announces $2 Million Public Offering

REVB

GlobeNewswire

a year ago

XORTX Announces $2 Million Public Offering

Ohmyhome and Webuy Announce Strategic Collaboration to Cross-Sell Products and Services Across Singapore

REVB

GlobeNewswire

a year ago

Ohmyhome and Webuy Announce Strategic Collaboration to Cross-Sell Products and Services Across Singapore

Gold CEO Firing Deals Fresh Blow to Mining’s Battered Reputation

REVB

Bloomberg

a year ago

Gold CEO Firing Deals Fresh Blow to Mining’s Battered Reputation

Alpine 4 Holdings (ALPP) Announces Receipt of Nasdaq Notice of Additional Staff Determination

REVB

ACCESSWIRE

a year ago

Alpine 4 Holdings (ALPP) Announces Receipt of Nasdaq Notice of Additional Staff Determination

Banzai CEO Purchases Additional Shares in Market

REVB

GlobeNewswire

a year ago

Banzai CEO Purchases Additional Shares in Market

AppTech Engages CORE IR for Investor Relations and Shareholder Communications Services

REVB

GlobeNewswire

a year ago

AppTech Engages CORE IR for Investor Relations and Shareholder Communications Services

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

REVB

ACCESSWIRE

a year ago

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

REVB

GlobeNewswire

a year ago

Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

Cazoo Announces Completion of Debt Restructuring and Related Transactions on December 6, 2023

REVB

Business Wire

a year ago

Cazoo Announces Completion of Debt Restructuring and Related Transactions on December 6, 2023

GD Culture Group’s Portfolio Company DigiTrax Unveils New AI Music Training Model License for Publishers, Composers, Producers, and Beatmakers

REVB

GlobeNewswire

a year ago

GD Culture Group’s Portfolio Company DigiTrax Unveils New AI Music Training Model License for Publishers, Composers, Producers, and Beatmakers

Clean Energy Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update

REVB

GlobeNewswire

a year ago

Clean Energy Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update

Brera Tchumene promoted to Moçambola, football’s First Division in Mozambique

REVB

GlobeNewswire

a year ago

Brera Tchumene promoted to Moçambola, football’s First Division in Mozambique

Star Equity Holdings, Inc. Declares Cash Dividend of $0.25 Per Share of 10% Series A Cumulative Perpetual Preferred Stock

REVB

GlobeNewswire

2 years ago

Star Equity Holdings, Inc. Declares Cash Dividend of $0.25 Per Share of 10% Series A Cumulative Perpetual Preferred Stock

BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study

REVB

Zacks

2 years ago

BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study

REVB

Zacks Small Cap Research

2 years ago

REVB Releases Earnings and Prepares for Trials

REVB

Zacks Small Cap Research

2 years ago

REVB Releases Earnings and Prepares for Trials

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023

REVB

Business Wire

2 years ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023

REVB

Business Wire

2 years ago

CuriosityStream Announces Third Quarter 2023 Financial Results

Hydrofarm Holdings Group Announces Third Quarter 2023 Results

REVB

GlobeNewswire

2 years ago

Hydrofarm Holdings Group Announces Third Quarter 2023 Results

Luokung Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

REVB

GlobeNewswire

2 years ago

Luokung Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

REVB

Business Wire

2 years ago

Know Labs Expands Board of Directors

REVB

Business Wire

2 years ago

Latest Revelation Biosciences Inc. (REVB) News on May 22, 2025

Share on Social Networks: